---
title: "Speciality Medicines (SPML) — Share Price, Financials & Analysis"
symbol: "SPML"
company: "Speciality Medicines"
canonical: "https://tapetide.com/stocks/SPML"
isin: "INE0R0M01014"
nse_symbol: "SPECIALITYMEDICINESLTD"
bse_code: "SPML"
market_cap_cr: 152.76
generated_at: "2026-09-14T01:18:34.903Z"
---

# Speciality Medicines (SPML)

Canonical page: https://tapetide.com/stocks/SPML

## Company

- **NSE Symbol:** SPECIALITYMEDICINESLTD
- **BSE Code:** SPML
- **ISIN:** INE0R0M01014
- **Stock Type:** EQUITY
- **F&O Eligible:** No

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:54:30.660326Z.

- **Market Cap:** ₹152.76 Cr
- **Classification:** SME
- **P/E (reported):** 10.7
- **Book Value:** ₹81.04
- **Price to Book:** 1.95
- **Dividend Yield:** 0%
- **ROE:** 28.3%
- **ROCE:** 27.61%
- **Debt to Equity:** 0.1
- **Revenue (yearly):** ₹75.29 Cr
- **Net Income:** ₹13.02 Cr
- **EBITDA:** ₹13.69 Cr
- **52-Week High:** ₹381.2
- **52-Week Low:** ₹121.1
- **RSI (14):** 49.28

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | -20.63% | -37.53% | — |
| ebitda margin growth | 12.45% | -7.79% | 219.36% |
| net income growth | 51.4% | 98% | 768% |
| revenue growth | 28.7% | 48% | 13.26% |
| roce | -14.57% | -40.88% | 54.49% |
| roe | 45.35% | 25.52% | -1.67% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 | Mar 2026 |
| --- | --- | --- |
| Sales | 31 | 45 |
| Expenses | 26 | 36 |
| Operating Profit | 4 | 8 |
| OPM % | 14 | 19 |
| Other Income | 0 | 1 |
| Interest | 0 | 1 |
| Depreciation | 0 | 0 |
| Profit before tax | 4 | 8 |
| Tax % | 36 | -1 |
| Net Profit | 3 | 8 |
| EPS in Rs | 4.16 | 9.31 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 40 | 23 | 28 | 58 | 75 |
| Expenses | 38 | 20 | 22 | 49 | 62 |
| Operating Profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6 | 15 | 19 | 16 | 18 |
| Other Income | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | 5 | 9 | 13 |
| Tax % | 31 | 43 | 36 | 1 | 0 |
| Net Profit | 1 | 2 | 3 | 9 | 13 |
| EPS in Rs | 70.48 | 4.42 | 5.73 | 13.38 | 14.83 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.21 | 4 | 5 | 6 | 9 |
| Reserves | 2 | 2 | 10 | 24 | 62 |
| Borrowings | 1 | 4 | 3 | 5 | 7 |
| Other Liabilities | 3 | 4 | 5 | 5 | 17 |
| Total Liabilities | 6 | 13 | 23 | 40 | 95 |
| Fixed Assets | 2 | 2 | 1 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 11 | 21 | 38 | 93 |
| Total Assets | 6 | 13 | 23 | 40 | 95 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 1 | -4 | -5 | -6 | -1 |
| Cash from Investing Activity | -2 | 0 | 0 | -2 | -3 |
| Cash from Financing Activity | 2 | 4 | 5 | 8 | 28 |
| Net Cash Flow | 0 | 0 | 0 | 1 | 24 |
| Free Cash Flow | -1 | -4 | -5 | -6 | -1 |
| CFO/OP | 36 | -101 | -66 | -63 | -9 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 23 | 87 | 142 | 60 | 128 |
| Inventory Days | 5 | 103 | 161 | 150 | 191 |
| Days Payable | 12 | 40 | 48 | 8 | 80 |
| Cash Conversion Cycle | 16 | 149 | 255 | 202 | 239 |
| Working Capital Days | -3 | 76 | 185 | 180 | 221 |
| ROCE % | — | 52 | 38 | 34 | 25 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2025 | Mar 2026 |
| --- | --- | --- |
| Promoters | 62.39% | 43.43% |
| FIIs | 0% | 0.24% |
| DIIs | 0% | 0% |
| Government | 0% | 0% |
| Public | 0% | 48.57% |
| Others | 37.61% | 7.77% |
| No. of Shareholders | 97 | 103 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 7 / 6 / 6

### Moving Averages — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 153.05 | Buy |
| EMA (10) | 156.04 | Buy |
| SMA (20) | 155.54 | Buy |
| EMA (20) | 157.46 | Buy |
| SMA (50) | 169.89 | Sell |
| EMA (50) | 171.5 | Sell |
| SMA (100) | 210.07 | Sell |
| EMA (100) | 199.67 | Sell |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 56.55 | Neutral |
| MACD (12,26,9) | -3.77 | Buy |
| Stochastic (14,3,3) | 81.92 | Sell |
| ADX (14) | 25.19 | Buy |
| Williams %R (14) | -25.47 | Neutral |
| ATR (14) | 6.93 | High Volatility |
| ROC (12) | 7.17 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 56.75 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-05 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dbc88836-e606-4063-b368-398fd6a02dfd.pdf) |
| 2026-09-03 | [Board Meeting Outcome for Outcome Of Board Meeting Held On September 03 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c8df00c-0ae0-4b94-87ba-60c3ee81a1ed.pdf) |
| 2026-09-03 | [Notice Of 5Th Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c7fd650-53c0-48f2-add6-e0fdc2b0a555.pdf) |
| 2026-09-03 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=817eea60-3cdb-4062-a9dd-6c12046e3936.pdf) |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77f29b7d-7da6-464e-ab1a-f9487e6bc9d8.pdf) |
| 2026-08-12 | [Intimation Under Regulation 30 Of The SEBI (LODR) Regulations 2015 Regarding Approval For Two New Products In Ethiopia](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2fb8f869-81a0-4526-9dd9-fb22ecf0e9cd.pdf) |
| 2026-08-04 | [Intimation Under Regulation 30 Of The SEBI (LODR) Regulations 2015 Regarding Appointment Of Investor And Public Relations Agency Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a21e10c4-7f42-4915-ab96-fdc0b65f0150.pdf) |
| 2026-07-06 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6710af1-f96b-4edb-a193-5f3238e1838e.pdf) |
| 2026-05-28 | [Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E On May 28 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16e06da0-ed3b-4c63-b4f7-b0c9ce0c1905.pdf) |
| 2026-05-21 | [Board Meeting Intimation for Meeting Of Board Of Directors Of Speciality Medicines Limited To Be Held On May 28 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55d20cb1-4289-4702-bbc7-81e35045476c.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-05-28 | [Results - Financial Results For The Half Year And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1bf6ccc1-b7f5-4ea8-9007-0c6a95971fa1.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 31 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for year/half-year ended March 31, 2026. | [Closure of Trading Window 31 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for year/half-year ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3bd39ec2-6313-406c-8c94-908c1a090d6e.pdf) |
| 2d - Company clarifies share price movement is market-driven; no undisclosed material event. | [Reply To Clarification Sought On Price Movement By Stock Exchange 2d - Company clarifies share price movement is market-driven; no undisclosed material event.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0235213f-7175-4f5e-9a24-f71a1cd14428.pdf) |
| 28 Apr - Company disclosed KMP contact details for Regulation 30(5) and uploaded them on website. | [Intimation Of Contact Details Of Key Managerial Personnel Pursuant To Regulation 30(5) Of SEBI (LODR) Regulations 2015 28 Apr - Company disclosed KMP contact details for Regulation 30(5) and uploaded them on website.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3b19617f-fcef-493f-9424-ceaec6d09c5c.pdf) |
| 28 Apr - Company disclosed KMP contact details for Regulation 30(5) and uploaded them on website. | [Intimation Of Contact Details Of Key Managerial Personnel Pursuant To Regulation 30(5) Of SEBI (LODR) Regulations 2015 28 Apr - Company disclosed KMP contact details for Regulation 30(5) and uploaded them on website.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/3b19617f-fcef-493f-9424-ceaec6d09c5c.pdf) |
| 28 Apr - Board met on 28 April 2026, appointed secretarial and internal auditors, and authorised KMP for disclosures. | [Announcement under Regulation 30 (LODR)-Change in Management 28 Apr - Board met on 28 April 2026, appointed secretarial and internal auditors, and authorised KMP for disclosures.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f490fbc1-6afd-4dbc-a379-2f01bc4a7d8d.pdf) |
| 28 Apr - Board met on 28 April 2026, appointed secretarial and internal auditors, and authorised KMP for disclosures. | [Announcement under Regulation 30 (LODR)-Change in Management 28 Apr - Board met on 28 April 2026, appointed secretarial and internal auditors, and authorised KMP for disclosures.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f490fbc1-6afd-4dbc-a379-2f01bc4a7d8d.pdf) |
| 28 Apr - Board appointed secretarial and internal auditors; authorised KMP and reviewed related party transactions. | [Board Meeting Outcome for Outcome Of Board Meeting Held On April 28 2026 28 Apr - Board appointed secretarial and internal auditors; authorised KMP and reviewed related party transactions.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/55622518-e0ec-4ec8-8594-f613cc2cd295.pdf) |
| 28 Apr - Board appointed secretarial and internal auditors; authorised KMP and reviewed related party transactions. | [Board Meeting Outcome for Outcome Of Board Meeting Held On April 28 2026 28 Apr - Board appointed secretarial and internal auditors; authorised KMP and reviewed related party transactions.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/55622518-e0ec-4ec8-8594-f613cc2cd295.pdf) |
| 23 Apr - Speciality Medicines signed a USD 2 million distribution deal with an international entity. | [Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 23 Apr - Speciality Medicines signed a USD 2 million distribution deal with an international entity.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/923f0d70-534d-4f2c-9eae-b852a5333210.pdf) |
| 22 Apr - Company finalizes USD 1.5 million distribution deal with an international entity. | [Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 22 Apr - Company finalizes USD 1.5 million distribution deal with an international entity.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/eb51db55-690f-43ee-926a-baf4ab679a17.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-14T01:18:34.903Z.